Corn Ethanol Byproduct Yields Peptides That Inhibit Both Blood Pressure and Blood Sugar Enzymes

Two-step enzymatic hydrolysis of corn distillers solubles (CDS) protein using alcalase followed by flavourzyme (AF) produced peptides with 97.68% ACE inhibition and 51.51% DPP4 inhibition — the highest dual bioactivity among all hydrolysis combinations tested. Nine novel peptides were identified by mass spectrometry from the most active fraction (<3 kDa), including APLA, PLFP, LFLP, LPPYL, PLYPLP, NDWHTGPL, LPPYLPS, GSPFLGQ, and SWQQPIVGG. Bioinformatic analysis confirmed these peptides can bind to the active sites of both ACE and DPP4 enzymes.

Laboratory study comparing one-step (alcalase, trypsin, or flavourzyme alone) and two-step (6 sequential combinations) enzymatic hydrolysis of CDS proteins. Hydrolysates were evaluated for yield, protein content, degree of hydrolysis, ACE inhibition, and DPP4 inhibition. The most active hydrolysate (AF, alcalase then flavourzyme) was fractionated to <3 kDa and analyzed by mass spectrometry to identify peptide sequences. Bioinformatic analysis and molecular docking assessed peptide binding to ACE and DPP4 active sites.

Corn distillers solubles are a low-value byproduct of ethanol production that is largely underutilized. Finding that these waste proteins can be converted into peptides with dual blood pressure-lowering (ACE inhibition) and blood sugar-regulating (DPP4 inhibition) activity transforms industrial waste into a potential source of functional food ingredients. This approach adds value to agricultural byproducts while addressing two of the most prevalent chronic diseases — hypertension and type 2 diabetes.

The search for food-derived peptides with health benefits is a rapidly growing field. Finding dual-activity peptides (targeting both blood pressure and blood sugar pathways) from an abundant agricultural waste stream is particularly attractive — it combines sustainability goals with functional food development. If validated in vivo, these peptides could join the ranks of other food-derived bioactive peptides like casein-derived lactotripeptides used in blood pressure-lowering dairy products.

This is entirely an in vitro and computational study — no animal or human testing was performed. The inhibitory activities measured in test tubes may not translate to actual blood pressure or blood sugar effects in the body, as peptides must survive digestion and reach their targets. Bioavailability and stability of these peptides in the gastrointestinal tract were not assessed.